Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.

@article{AlhencGelas1994AdjustedVF,
  title={Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.},
  author={Martine Alhenc-Gelas and C Jestin-Le Guernic and Jeanne Vitoux and Andr{\'e} Kher and Martine Aiach and Jean-noel Fiessinger},
  journal={Thrombosis and haemostasis},
  year={1994},
  volume={71 6},
  pages={698-702}
}
Treatment monitoring based on a laboratory parameter increases the efficacy and safety of standard heparin therapy, but it is not known if this also applies to low-molecular-weight heparin (LMWH) therapy of acute deep vein thrombosis (DVT). In a prospective randomized trial involving 122 consecutive patients, group A (58 patients) received a weight adjusted dose of Fragmin (100 IU/kg) subcutaneously twice a day throughout the treatment period (10 days +/- 1), while in group B (64 patients) the… CONTINUE READING